SciSparc Ltd. (NASDAQ:SPRC) Short Interest Update

SciSparc Ltd. (NASDAQ:SPRC) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totalling 831,500 shares, an increase of 203.7% from the September 15th total of 273,800 shares. Based on an average daily volume of 3,730,000 shares, the days-to-cover ratio is currently 0.2 days. Approximately 8.0% of the company’s shares are short sold.

SciSparc Price Performance

Shares of SPRC remained flat at $0.22 during trading hours on Friday. 196,027 shares of the company were exchanged, compared to its average volume of 1,700,189. SciSparc has a 1-year low of $0.21 and a 1-year high of $14.22. The company’s 50 day moving average is $0.31 and its 200-day moving average is $0.83.

Institutional Investors Weigh In On SciSparc

An institutional investor recently bought a new position in SciSparc stock. Renaissance Technologies LLC bought a new position in shares of SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 25.06% of the company’s stock.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.